<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:10:12Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10196432" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10196432</identifier>
        <datestamp>2023-05-20</datestamp>
        <setSpec>cptpsp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3-mathml3.xsd" dtd-version="1.3" id="psp412892" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2163-8306</journal-id>
              <journal-id journal-id-type="publisher-id">PSP4</journal-id>
              <journal-title-group>
                <journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2163-8306</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10196432</article-id>
              <article-id pub-id-type="pmcid">PMC10196432</article-id>
              <article-id pub-id-type="pmc-uid">10196432</article-id>
              <article-id pub-id-type="pmid">36919202</article-id>
              <article-id pub-id-type="pmid">36919202</article-id>
              <article-id pub-id-type="doi">10.1002/psp4.12892</article-id>
              <article-id pub-id-type="publisher-id">PSP412892</article-id>
              <article-id pub-id-type="other">PSP-2022-0049-T</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Articles</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis</article-title>
                <alt-title alt-title-type="right-running-head">Malaria and malnturtion in Ugandan children</alt-title>
                <alt-title alt-title-type="left-running-head">Ali et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="psp412892-cr-0001" contrib-type="author">
                  <name>
                    <surname>Ali</surname>
                    <given-names>Ali Mohamed</given-names>
                  </name>
                  <xref rid="psp412892-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="psp412892-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="psp412892-cr-0002" contrib-type="author">
                  <name>
                    <surname>Wallender</surname>
                    <given-names>Erika</given-names>
                  </name>
                  <xref rid="psp412892-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="psp412892-cr-0003" contrib-type="author">
                  <name>
                    <surname>Hughes</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <xref rid="psp412892-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="psp412892-cr-0004" contrib-type="author">
                  <name>
                    <surname>Dorsey</surname>
                    <given-names>Grant</given-names>
                  </name>
                  <xref rid="psp412892-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="psp412892-cr-0005" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Savic</surname>
                    <given-names>Radojka M.</given-names>
                  </name>
                  <xref rid="psp412892-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>rada.savic@ucsf.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="psp412892-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Bioengineering and Therapeutic Sciences</named-content>
                <institution>University of California San Francisco</institution>
                <city>San Francisco</city>
                <named-content content-type="country-part">California</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="psp412892-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Bagamoyo Research and Training Center</named-content>
                <institution>Ifakara Health Institute</institution>
                <city>Bagamoyo</city>
                <country country="TZ">Tanzania</country>
              </aff>
              <aff id="psp412892-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Clinical Pharmacy</named-content>
                <institution>University of California, San Francisco</institution>
                <city>San Francisco</city>
                <named-content content-type="country-part">California</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="psp412892-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of California, San Francisco</institution>
                <city>San Francisco</city>
                <named-content content-type="country-part">California</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Radojka M. Savic, 1700 4th Street, UCSF Box 2552, Room 503C, San Francisco, CA 94143, USA.<break/>
Email: <email>rada.savic@ucsf.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="140">5</issue>
              <issue-id pub-id-type="doi">10.1002/psp4.v12.5</issue-id>
              <fpage>656</fpage>
              <lpage>667</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>30</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>01</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>06</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 ASCPT-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:PSP4-12-656.pdf"/>
              <abstract>
                <title>Abstract</title>
                <p>African children are at risk of malaria and malnutrition. We quantified relationships between malaria and malnutrition among young Ugandan children in a high malaria transmission region. Data were used from a randomized controlled trial where Ugandan HIV‐unexposed (<italic toggle="no">n</italic> = 393) and HIV‐exposed (<italic toggle="no">n</italic> = 186) children were randomized to receive no malaria chemoprevention, monthly sulfadoxine‐pyrimethamine, daily trimethoprim‐sulfamethoxazole, or monthly dihydroartemisinin‐piperaquine (DP) from age 6–24 months, and then were followed off chemoprevention until age 36 months. Monthly height and weight, and time of incident malaria episodes were obtained; 89 children who received DP contributed piperaquine (PQ) concentrations. Malaria hazard was modeled using parametric survival analysis adjusted for repeated events, and height and weight were modeled using a Brody growth model. Among 579 children, stunting (height‐for‐age z‐score [ZHA] &lt; −2) was associated with a 17% increased malaria hazard (95% confidence interval [CI] 10–23%) compared with children with a ZHA of zero. DP was associated with a 35% lower malaria hazard (hazard ratio [HR] [95% CI], 0.65 [0.41–0.97]), compared to no chemoprevention. After accounting for PQ levels, stunted children who received DP had 2.1 times the hazard of malaria (HR [95% CI] 2.1 [1.6–3.0]) compared with children with a ZHA of zero who received DP. Each additional malaria episode was associated with a 0.4% reduced growth rate for height. Better dosing regimens are needed to optimize malaria prevention in malnourished populations, but, importantly, malaria chemoprevention may reduce the burden of malnutrition in early childhood.</p>
              </abstract>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Bill and Melinda Gates Foundation
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000865</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>OPP1191117</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="4"/>
                <page-count count="12"/>
                <word-count count="6553"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>May 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.8 mode:remove_FC converted:19.05.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="PSP412892-cit-2001"><string-name><surname>Ali</surname><given-names>AM</given-names></string-name>, <string-name><surname>Wallender</surname><given-names>E</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>E</given-names></string-name>, <string-name><surname>Dorsey</surname><given-names>G</given-names></string-name>, <string-name><surname>Savic</surname><given-names>RM</given-names></string-name>. <article-title>Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2023</year>;<volume>12</volume>:<fpage>656</fpage>‐<lpage>667</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.12892</pub-id>
</mixed-citation>
              </p>
              <fn-group id="psp412892-ntgp-0001">
                <fn fn-type="equal" id="psp412892-note-0001">
                  <p>Ali Mohamed Ali and Erika Wallender contributed equally to this work.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="psp412892-body-0001">
            <boxed-text position="float" content-type="box" id="psp412892-blk-0001">
              <caption>
                <title>Study Highlights</title>
              </caption>
              <p>
                <bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
              </p>
              <p>The greatest burdens of malnutrition and malaria overlap in sub‐Saharan Africa, but little is known about the relationships among malnutrition, malaria, and the efficacy of malaria chemoprevention.</p>
              <p>
                <bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
              </p>
              <p>We used parametric survival and growth models to answer whether malnutrition is associated with an increased hazard of malaria and whether malaria is associated with decreased childhood growth.</p>
              <p>
                <bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
              </p>
              <p>We show that malnutrition severity is associated with an increased hazard of incident malaria even when effective malaria chemoprevention is administered. Additionally, our findings indicate that each additional episode of malaria is associated with a reduced growth rate for height.</p>
              <p>
                <bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
              </p>
              <p>This study highlights the importance of including malnourished children in clinical trials. Stunted children have a higher risk of malaria regardless of chemoprevention regimen, suggesting that more work is needed to optimize chemoprevention regimens for this population. Future clinical trials should (1) be powered to evaluate malnutrition as a covariate and (2) incorporate evaluation of nonmalarial outcomes, including malnutrition/childhood growth.</p>
            </boxed-text>
            <sec id="psp412892-sec-0003">
              <title>INTRODUCTION</title>
              <p>Malaria and malnutrition are significant causes of morbidity and mortality in young children in sub‐Saharan Africa. Children less than 5 years of age accounted for 77% of malaria deaths globally in 2020,<xref rid="psp412892-bib-0001" ref-type="bibr"><sup>1</sup></xref> and malnutrition is present in nearly half of all young children who die.<xref rid="psp412892-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="psp412892-bib-0003" ref-type="bibr"><sup>3</sup></xref> The estimated 58.7 million malnourished children residing in Africa are frequently also at high risk of falciparum malaria.<xref rid="psp412892-bib-0004" ref-type="bibr"><sup>4</sup></xref> Although the burden of malaria and malnutrition overlap, a relationship between these conditions has been difficult to quantify as large cohorts with paired longitudinal malaria incidence and frequently measured anthropometric data are rarely available.</p>
              <p>Chronic malnutrition, as measured by low height‐for‐age z‐score (ZHA), in young African children has been associated with increased risk of malaria, severe malaria, and anemia.<xref rid="psp412892-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="psp412892-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="psp412892-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="psp412892-bib-0008" ref-type="bibr"><sup>8</sup></xref> Proposed mechanisms for this observation include lower antimalarial immunity,<xref rid="psp412892-bib-0009" ref-type="bibr"><sup>9</sup></xref> lower exposure to antimalarial drugs due to poor absorption or poorly assigned weight‐bands for pediatric dosing,<xref rid="psp412892-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="psp412892-bib-0011" ref-type="bibr"><sup>11</sup></xref> or less access to malaria control measures.<xref rid="psp412892-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="psp412892-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="psp412892-bib-0014" ref-type="bibr"><sup>14</sup></xref> Despite these observations, it is unclear how best to incorporate malnutrition in malaria chemoprevention or other malaria control efforts. Quantifying the contribution of malnutrition to malaria risk is key to reducing the malaria burden in young African children.</p>
              <p>It is also likely that malaria exacerbates malnutrition. Use of long‐lasting insecticide treated bed nets (LLINs) for malaria prevention led to greater weight and height gains in children when compared to no LLIN use.<xref rid="psp412892-bib-0015" ref-type="bibr"><sup>15</sup></xref> However, the majority of studies that examined relationships between malaria and risk of malnutrition showed no relationship. These studies had important limitations, including infrequent anthropometric measurements, lack of malaria incidence data, or cohort enrollment in regions with seasonal or low malaria transmission.<xref rid="psp412892-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="psp412892-bib-0017" ref-type="bibr"><sup>17</sup></xref> Malaria likely worsens childhood malnutrition to the greatest degree in regions with high perennial transmission. Resolving uncertainty around the interplay between malaria and malnutrition would allow us to better target malaria control and nutritional interventions.</p>
              <p>We identified and quantified risk factors for malaria and malnutrition in a large cohort of Ugandan children who were followed from 6 months to 3 years of age as part of two randomized controlled trials of three malaria chemoprevention regimens.<xref rid="psp412892-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="psp412892-bib-0019" ref-type="bibr"><sup>19</sup></xref> Using this unique dataset with frequent anthropometric measurements, comprehensive covariate data, including drug concentrations, and accurate malaria incidence measurement, we used quantitative modeling techniques to estimate how changes in malaria burden or malnutrition impact future growth and malaria incidence, respectively. We conducted simulations to quantify the relationship between malaria and childhood growth.</p>
            </sec>
            <sec sec-type="methods" id="psp412892-sec-0004">
              <title>METHODS</title>
              <sec id="psp412892-sec-0005">
                <title>Study design and participants</title>
                <p>Data from two randomized controlled malaria chemoprevention trials conducted concurrently in the same clinic in Tororo, Uganda, from June 2010 through September 2013 were used.<xref rid="psp412892-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="psp412892-bib-0019" ref-type="bibr"><sup>19</sup></xref> Eligible children were 4–5 months of age, lived within 30‐km of the study clinic, and were HIV‐uninfected with known HIV status of the mother. One trial enrolled HIV‐unexposed children (the mother was HIV‐uninfected) and one trial enrolled HIV‐exposed children (the mother was HIV‐infected). At enrollment every household was given two LLINs and the caregiver participated in a sociodemographic survey. These studies were approved by ethics committees at Makerere University, the Ugandan National Council of Science and Technology, and the University of California, San Francisco, and a signed written informed consent form was obtained from all parents/guardians. Both studies were listed under the same clinical trial registration number: NCT00948896.</p>
              </sec>
              <sec id="psp412892-sec-0006">
                <title>Study procedures</title>
                <p>HIV‐unexposed children began chemoprevention at 6 months of age and, because HIV‐exposed participants received daily trimethoprim‐sulfamethoxazole (TS) while breastfeeding per national guidelines, they began chemoprevention at 6 months of age or upon breastfeeding cessation, whichever was later. All participants received chemoprevention until 24 months of age and were followed off chemoprevention until 36 months of age. Children were randomized in equal numbers to no chemoprevention, a once monthly dose of sulfadoxine‐pyrimethamine (SP), a daily dose of TS, or a monthly treatment course (daily dosing for 3 consecutive days) of dihydroartemisinin‐piperaquine (DP). Each regimen was administered according to weight‐bands specified by the manufacturer at the time of the study (Table <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S4</xref> and Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S6</xref>).<xref rid="psp412892-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="psp412892-bib-0019" ref-type="bibr"><sup>19</sup></xref> Parents and guardians were given supplies of the study drugs to be taken unobserved at home and accurate adherence data were not available.</p>
                <p>Children received all medical care at a dedicated study clinic to ensure accurate diagnosis of incident malaria. Children returned monthly for weight and height measurements and the parent/guardian was asked if the child had breast fed in the last 7 days. At any visit, if a child had a fever (&gt;37.5°C) or a history of fever within the last 24 h, a thick blood smear was taken to evaluate for malaria. If the blood smear was positive, the child was diagnosed with and treated for malaria. The time of incident malaria was defined as the day of a visit where malaria was diagnosed which occurred greater than 14 days after a prior episode.</p>
                <p>Monthly age, weight, and height measurements were used to calculate weight‐for‐age z‐score (WAZ), ZHA, and weight‐for‐height z‐score (WHZ). Z‐scores were calculated using the World Health Organization's (WHO) Anthro macro.<xref rid="psp412892-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="psp412892-bib-0021" ref-type="bibr"><sup>21</sup></xref> A child was considered underweight, stunted, or wasted if they had a WAZ less than −2, ZHA less than −2, or WHZ less than −2, respectively. Z‐scores considered physiologically implausible by the WHO macro were excluded from the analysis (<xref rid="psp412892-supitem-0001" ref-type="supplementary-material">Supplemental Methods</xref>).</p>
              </sec>
              <sec id="psp412892-sec-0007">
                <title>Piperaquine assay and piperaquine concentration data</title>
                <p>A subset of HIV‐unexposed children who received DP underwent sampling of venous plasma to determine piperaquine (PQ) concentrations.<xref rid="psp412892-bib-0022" ref-type="bibr"><sup>22</sup></xref> PQ concentrations were measured either at malaria diagnosis or at routine study visits at 4 month intervals using a validated liquid chromatography and tandem mass spectrometry method.<xref rid="psp412892-bib-0023" ref-type="bibr"><sup>23</sup></xref> As DP was taken at home without directly observed therapy, PQ concentrations were not linked to specific dosing events in this analysis. The plasma assay had a quantification range of 1.5–250 ng/ml with 1.5 ng/ml as the lower limit of quantification (LLOQ).</p>
              </sec>
              <sec id="psp412892-sec-0008">
                <title>Parametric survival analysis</title>
                <p>A parametric survival model, adjusted for repeated events, was developed to estimate the hazard of incident malaria from 6 to 24 months of age, during chemoprevention. The Laplace estimation method in NONMEM, version 7.4.2 was used.<xref rid="psp412892-bib-0024" ref-type="bibr"><sup>24</sup></xref> The baseline hazard was estimated for all children, and individually by treatment arm. Exponential, Weibull, and Gompertz distributions were tested as the baseline hazard model. Events were right censored at the participant's last visit if before 24 months of age, or at the end of chemoprevention at 24 months. Covariates were tested on baseline hazard using stepwise covariate modeling (SCM) with a <italic toggle="yes">p</italic> value of less than 0.05 for forward inclusion and a <italic toggle="yes">p</italic> value of less than 0.01 for backward elimination using linear and exponential functions.<xref rid="psp412892-bib-0024" ref-type="bibr"><sup>24</sup></xref> Covariates determined at the start of chemoprevention included sex, chemoprevention regimen, HIV exposure status, use of other malaria prevention methods (keeping doors and windows closed in the evening, emptying/covering water sources assessed at the start of the study), and derived socioeconomic tertile. Time‐varying covariates included age (as HIV‐exposed and ‐unexposed children could begin chemoprevention at different ages), weight, WAZ, ZHA, and WHZ. If malnutrition status was missing at a routine visit, the prior measurement was carried forward. HIV exposure status, chemoprevention arm, use of malaria prevention measures, and socioeconomic tertile were available for all individuals.</p>
                <p>Model selection was guided by change in objective function value (OFV) between nested models, parameter estimates, relative standard error (RSE), and Kaplan–Meier visual predictive check.<xref rid="psp412892-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="psp412892-bib-0026" ref-type="bibr"><sup>26</sup></xref>
</p>
                <p>Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using the final parameter estimates and covariance matrices. Percent reductions in incident malaria hazard were defined as 1 – the HR. For the final models, 95% CIs of parameter estimates were determined by bootstrap (<italic toggle="yes">n</italic> = 1000).</p>
              </sec>
              <sec id="psp412892-sec-0009">
                <title><styled-content style="fixed-case" toggle="no">Sub‐analysis</styled-content> using <styled-content style="fixed-case" toggle="no">PQ</styled-content> concentration data</title>
                <p>Drug concentration data were available for a subset of 89 HIV‐unexposed children, and a stand‐alone parametric survival model was developed to assess the impact of PQ concentration on malaria hazard among the subset of children with at least one PQ concentration. After baseline model selection, covariate analysis using SCM was performed as described above. All covariates tested are listed in the <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">Supplementary Methods</xref>.</p>
              </sec>
              <sec id="psp412892-sec-0010">
                <title>Growth models</title>
                <p>Growth models were developed to predict height and weight from 6 months to 3 years of age. Monthly height, weight, and age measurements were described using a Brody growth model (Equations listed in <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">Supplementary Methods</xref>). Covariate relationships were also explored for the baseline height/weight, the maximum height/weight, and growth rate (KTR).<disp-formula id="psp412892-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>KTR</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>α</mml:mi><mml:mo linebreak="goodbreak">×</mml:mo><mml:msup><mml:mi>Age</mml:mi><mml:mi>β</mml:mi></mml:msup><mml:mo linebreak="goodbreak">×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mi mathvariant="normal">η</mml:mi></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>The equation for growth rate is shown in Equation 1, where <mml:math id="jats-math-2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>α</mml:mi><mml:mspace width="0.25em"/></mml:mrow></mml:mrow></mml:math> is the typical growth rate, <mml:math id="jats-math-3" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>β</mml:mi><mml:mspace width="0.25em"/></mml:mrow></mml:mrow></mml:math> is the parameter for the age function, and <italic toggle="yes">η</italic> is the residual error. Covariates included those listed above as well as time varying cumulative number of malaria episodes, and whether or not the child was breast fed in the last 7 days. If an individual was lost to follow‐up, their data were included until they left the study. If height or other covariate data was missing at a routine visit, the prior measurement was carried forward. For the final model, 95% CIs of the parameter estimates were determined by bootstrap (<italic toggle="yes">n</italic> = 1000).</p>
              </sec>
              <sec id="psp412892-sec-0011">
                <title>Simulations</title>
                <p>The final survival models were used for simulations (<italic toggle="yes">n</italic> = 1000) to predict the total number of malaria episodes in stunted (ZHA = −2.1) and non‐stunted (ZHA = 0) children. For simulations, children were assumed to be HIV‐unexposed and in the low or middle socioeconomic category. For the DP arm, we conducted 1000 simulations of the above patients, but stratified into groups with PQ concentrations consistently greater than 10.3 ng/ml or less than or equal to 10.3 ng/ml.<xref rid="psp412892-bib-0027" ref-type="bibr"><sup>27</sup></xref> A sensitivity analysis with higher PQ target concentrations is described in the <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">Supplementary Results</xref>.<xref rid="psp412892-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="psp412892-bib-0029" ref-type="bibr"><sup>29</sup></xref>
</p>
                <p>Simulations using the final growth model for height were used to predict the proportion of stunted (ZHA = −2.1) children at 3 years of age, stratified by cumulative malaria episodes. Four datasets comprised of baseline WHZ, ZHA, sex, HIV exposure status, and time varying cumulative malaria episodes (0, 5 [lower 25th percentile of data], 11 [median of data] or 17 [upper 75th percentile of data]) from 6 months to 3 years of age were simulated 100 times. Predicted ZHA was calculated using the WHO Anthro macro.<xref rid="psp412892-bib-0021" ref-type="bibr"><sup>21</sup></xref>
</p>
              </sec>
            </sec>
            <sec sec-type="results" id="psp412892-sec-0012">
              <title>RESULTS</title>
              <sec id="psp412892-sec-0013">
                <title>Study participants and raw data</title>
                <p>Among the 579 children included in the analysis, 186 (32.1%) were HIV‐exposed. HIV‐exposed children were older when they began study drugs compared with HIV‐unexposed children (median age: 10 months vs. 6 months) and had lower median Z‐scores (Table <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S1</xref>). In total, 526 children were followed to the end of chemoprevention through 24 months of age (352 HIV‐unexposed and 174 HIV‐exposed), and 511 children were followed to 36 months of age (340 HIV‐unexposed and 171 HIV‐exposed). Baseline characteristics stratified by chemoprevention regimen did not differ (Table <xref rid="psp412892-tbl-0001" ref-type="table">1</xref>). Malaria outcomes by chemoprevention arm have been previously reported.<xref rid="psp412892-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="psp412892-bib-0019" ref-type="bibr"><sup>19</sup></xref> Briefly, 493 (85.1%) children experienced at least one malaria episode. During chemoprevention from 6–24 months of age, children in the no chemoprevention and SP arms had the highest number of malaria episodes (Table <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S2</xref>). After the first malaria episode, stunted children (ZHA &lt; −2) had an increased hazard of subsequent incident malaria for all treatment arms (Figure <xref rid="psp412892-fig-0001" ref-type="fig">1</xref>) and regardless of HIV exposure status (Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S1</xref>).</p>
                <table-wrap position="float" id="psp412892-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Characteristics of study participants at the start of chemoprevention</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic<xref rid="psp412892-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="char" valign="bottom" rowspan="1" colspan="1">No chemoprevention</th>
                        <th align="char" valign="bottom" rowspan="1" colspan="1">Daily TS</th>
                        <th align="char" valign="bottom" rowspan="1" colspan="1">Monthly SP</th>
                        <th style="border-bottom:solid 1px #000000" align="char" valign="bottom" rowspan="1" colspan="1">Monthly DP</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic toggle="yes">N</italic>
                        </td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">144</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">146</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">144</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">145</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">70 (48.6)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">75 (51.4)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">65 (45.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">77 (53.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HIV‐exposed,<xref rid="psp412892-note-0004" ref-type="table-fn"><sup>b</sup></xref>
<italic toggle="yes">n</italic> (%)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">46 (31.9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">47 (32.2)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">46 (31.9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">47 (32.4)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">Age in months</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV‐unexposed</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6.1 (6.0, 6.2)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6.1 (6.0, 6.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6.1 (6.0, 6.4)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6.1 (6.0, 6.3)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV‐exposed</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">10.0 (7.6, 16.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">11.6 (7.4, 18.0)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">9.3 (6.8, 18.4)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">10.3 (6.5 17.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight in kg</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">7.2 (5.7, 10.0)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6.7 (5.3, 9.8)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (5.3, 9.7)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6.8 (5.7, 9.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight‐for‐age z‐score</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.39 (−2.8, 1.4)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.58 (−3.2, 1.6)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.53 (−3.3, 1.3)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.51 (−3.2, 1.3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Height‐for‐age z‐score</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−1.26 (−3.6, 1.0)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.80 (−4.0, 1.5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−1.26 (−3.9, 0.9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−1.23 (−4.2, 0.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight‐for‐height z‐score</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.42 (−1.7, 2.4)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.02 (−2.6, 1.9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.25 (−1.9, 2.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.18 (−2.1, 2.3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Underweight,<xref rid="psp412892-note-0005" ref-type="table-fn"><sup>c</sup></xref>
<italic toggle="yes">n</italic> (%)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (9.7)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (13.7)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">21 (14.6)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">18 (12.4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Stunted,<xref rid="psp412892-note-0005" ref-type="table-fn"><sup>c</sup></xref>
<italic toggle="yes">n</italic> (%)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">37 (25.7)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">33 (22.6)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (27.8)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">34 (23.5)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Wasted,<xref rid="psp412892-note-0005" ref-type="table-fn"><sup>c</sup></xref>
<italic toggle="yes">n</italic> (%)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (1.4)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (5.5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (2.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (3.5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">Income strata, <italic toggle="yes">n</italic> (%)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Low</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">44 (30.5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">53 (36.3)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">52 (36.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">66 (45.5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Middle</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">59 (41.0)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">44 (30.1)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">49 (34.0)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">42 (29.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">41 (28.5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">49 (33.6)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">43 (29.9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">37 (25.5)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Other malaria prevention,<xref rid="psp412892-note-0005" ref-type="table-fn"><sup>c</sup></xref>
<italic toggle="yes">n</italic> (%)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">32 (22.2)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">33 (22.6)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (24.3)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">46 (31.7)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="psp412892-ntgp-0002">
                    <fn id="psp412892-note-0002">
                      <p>Abbreviations: DP, dihydroartemisinin‐piperaquine; SP, sulfadoxine‐pyrimethamine; TS, trimethoprim‐sulfamethoxazole.</p>
                    </fn>
                    <fn id="psp412892-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Continuous variables shown as median, (2.5th and 97.5th percentile).</p>
                    </fn>
                    <fn id="psp412892-note-0004">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>HIV‐exposed indicates children who are HIV‐uninfected but were born to HIV‐infected mothers.</p>
                    </fn>
                    <fn id="psp412892-note-0005">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Underweight: weight‐for‐age z‐score &lt; −2; Stunted: height‐for‐age z‐score &lt; −2; Wasted: weight‐for‐height z‐score &lt; −2; Other malaria prevention measures include keeping doors and windows closed in the evening, emptying/cover water sources.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" fig-type="FIGURE" id="psp412892-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Kaplan‐Meier curves stratified by chemoprevention and nutritional status (stunted: height‐for‐age z‐score &lt; −2 [orange line]; non‐stunted: height‐for‐age Z‐score ≥ −2 [blue line]). Time indicates time from beginning of chemoprevention to the subsequent malaria episode. DP, dihydroartemisinin‐piperaquine; SP, sulfadoxine‐pyrimethamine; TS, trimethoprim‐sulfamethoxazole.</p>
                  </caption>
                  <graphic xlink:href="PSP4-12-656-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>There were 500 PQ concentrations measured at the time of malaria (<italic toggle="yes">n</italic> = 283, 56.6%) or at monthly routine visits (<italic toggle="yes">n</italic> = 217, 43.4%) from 89 HIV‐unexposed children who received DP. The median PQ concentration was 5.6 ng/ml (range: LLOQ – 316 ng/ml). Children with a preceding PQ concentration of greater than 10.3 ng/ml had a lower cumulative hazard of repeated malaria events compared to when the preceding PQ concentration was less than or equal to 10.3 ng/ml (Figure <xref rid="psp412892-fig-0002" ref-type="fig">2</xref>).</p>
                <fig position="float" fig-type="FIGURE" id="psp412892-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Kaplan‐Meier curves for HIV‐unexposed participants who received dihydroartemisinin‐piperaquine and had piperaquine concentrations measured (<italic toggle="yes">n</italic> = 89), stratified by piperaquine concentration. Time indicates time from beginning of chemoprevention to the subsequent malaria episode. The green line indicates a concentration greater than &gt;10.3 ng/ml piperaquine preceding the malaria episode and purple line indicate a preceding PQ concentration of less than or equal to 10.3 ng/ml.</p>
                  </caption>
                  <graphic xlink:href="PSP4-12-656-g003" position="anchor" id="jats-graphic-3"/>
                </fig>
                <p>Height, weight, and age measurements were available from 27,890 (94.8%) of monthly study visits. Over 88% of measurements were below the WHO defined mean ZHA and 50% met the criteria for stunting (ZHA &lt; ‐2) at least once. Children who never developed malaria between 6 months and 3 years of age trended towards being taller than those who had malaria greater than or equal to one time (92.7 cm vs. 91.6 cm, <italic toggle="yes">p</italic> = 0.35; Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S2</xref>). Non‐stunted children at the start of chemoprevention who became stunted by 3 years of age had a trend toward a higher average number of malaria episodes compared with children who remained non‐stunted (median [5th‐95th percentiles] = 14 [3–29] vs. 12 [1–26], <italic toggle="yes">p</italic> = 0.18; Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S3</xref>).</p>
              </sec>
              <sec id="psp412892-sec-0014">
                <title>Parametric survival analysis</title>
                <p>An exponential survival distribution best predicted malaria for the no chemoprevention and SP regimens (Figure <xref rid="psp412892-fig-0003" ref-type="fig">3</xref>). A Weibull distribution provided the best survival distribution for TS (ΔOFV = −173) and DP (ΔOFV = −97.6), compared to an exponential distribution. After controlling for the prevention arm, socioeconomic tertile, and HIV exposure, greater ZHA (ΔOFV = −9.3) was associated with a reduced hazard of malaria (Table <xref rid="psp412892-tbl-0002" ref-type="table">2</xref>). ZHA and WAZ were correlated (correlation = 0.67, <italic toggle="yes">p</italic> value &lt; 0.001) and provided similar statistical significance and effect size. However, uncertainty in the covariate parameter estimate was higher (% relative standard error [%RSE] = 77.4) when WAZ was included compared to ZHA (%RSE = 17.8) and ZHA was included in the final model. Age, WHZ, weight, and sex were not associated with malaria hazard. The final survival function is shown in Equation 2.<disp-formula id="psp412892-disp-0002"><label>(2)</label><mml:math id="jats-math-4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo linebreak="goodbreak">×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>ZHA</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mo linebreak="goodbreak">−</mml:mo><mml:mn>1.32</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="goodbreak">×</mml:mo><mml:mi>HIV</mml:mi><mml:mspace width="0.25em"/><mml:mtext>exposed</mml:mtext></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo linebreak="goodbreak">×</mml:mo><mml:mtext>Highincome</mml:mtext></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mi>η</mml:mi></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">h</italic>(<italic toggle="yes">t</italic>) is the hazard; <italic toggle="yes">h</italic>
<sub>0</sub>(<italic toggle="yes">t</italic>) is the baseline hazard, −1.32 is the median ZHA of the population, and high income refers to the socioeconomic tertile with the highest income with low and middle income as the reference category, and <italic toggle="yes">η</italic> is the interindividual variability term.</p>
                <fig position="float" fig-type="FIGURE" id="psp412892-fig-0003">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Kaplan‐Meier visual predictive check of the parametric survival model for the first four malaria episodes. The observed data is denoted by the black and the 95% confidence interval of the simulated data is the blue shaded area. Each row of graphs describes survival for a consecutive malaria episode (labels on right side). Each column corresponds to a chemoprevention regimen. DP, dihydroartemisinin‐piperaquine; SP, sulfadoxine‐pyrimethamine; TS, trimethoprim‐sulfamethoxazole.</p>
                  </caption>
                  <graphic xlink:href="PSP4-12-656-g002" position="anchor" id="jats-graphic-5"/>
                </fig>
                <table-wrap position="float" id="psp412892-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Parameter estimates for parametric survival models predicting malaria</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Value (95% CI)<xref rid="psp412892-note-0007" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Between subject variability (95% CI)<xref rid="psp412892-note-0007" ref-type="table-fn"><sup>a</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Parametric survival analysis</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No chemoprevention and SP: Hazard (1/week)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.102 (0.093, 0.112)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">55. 6% (46.2, 64.5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TS: Hazard (1/week)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.067 (0.057, 0.077)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">78.6% (65.0, 94.7)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">TS: Shape parameter of Weibull</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">1.55 (1.44, 1.66)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">DP: Hazard (1/week)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.033 (0.025, 0.042)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">137% (105, 182)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">DP: Shape parameter of Weibull</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">1.39 (1.26, 1.51)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">16.1% (4.12, 22.0)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">Covariate effects on hazard</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Height‐for‐age z‐score</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.075 (−0.121, −0.0314)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV‐exposed<xref rid="psp412892-note-0008" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.236 (−0.348, −0.104)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Socioeconomic status</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Low + middle income</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">Ref</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High income</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.336 (−0.435, −0.227)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">Pharmacokinetic/pharmacodynamic analysis for piperaquine</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hazard (1/week)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.0494 (0.031, 0.080)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">78.9% (13.8, 145)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Shape parameter of Weibull</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">1.30 (1.01, 1.58)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">Covariate effect on hazard<xref rid="psp412892-note-0009" ref-type="table-fn"><sup>c</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PQ concentration &gt; 10.3 ng/ml</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.358 (−0.656, −0.228)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Height‐for‐age z‐score</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.355 (−0.482, −0.189)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="psp412892-ntgp-0003">
                    <fn id="psp412892-note-0006">
                      <p>Abbreviations: CI, confidence interval; DP, dihydroartemisinin‐piperaquine; PQ, piperaquine; RSE, relative standard error; SP, sulfadoxine‐pyrimethamine; TS, trimethoprim‐sulfamethoxazole.</p>
                    </fn>
                    <fn id="psp412892-note-0007">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>The 95% confidence intervals (CIs) were obtained.</p>
                    </fn>
                    <fn id="psp412892-note-0008">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>HIV‐exposed indicates children who are HIV‐uninfected but were born to HIV‐infected mothers.</p>
                      <p>Covariate relationship is as follows: <mml:math id="jats-math-5" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="0.25em"/><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">ZHA</mml:mi><mml:mo>−</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.32</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mi>HIV</mml:mi><mml:mspace width="0.25em"/><mml:mtext>exposed</mml:mtext></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">θ</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mtext>High income</mml:mtext></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mi mathvariant="normal">η</mml:mi></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math>
</p>
                    </fn>
                    <fn id="psp412892-note-0009">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Covariate relationship is given below (if PQ &gt;10.3, PQ concentration &gt; 10.3 equals 1, otherwise PQ concentration &gt; 10.3 is 0): <mml:math id="jats-math-6" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mi>PQ</mml:mi><mml:mspace width="0.25em"/><mml:mtext>Concentration</mml:mtext><mml:mo>&gt;</mml:mo><mml:mn>10.3</mml:mn></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">HAZ</mml:mi><mml:mo>+</mml:mo><mml:mn>1.1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mi>η</mml:mi></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math>
</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Compared to no chemoprevention, there was no difference in hazard of malaria in the SP arm, and these study arms were combined in the analysis. For the TS arm, although there was a 77% reduction in the hazard (HR [95% CI] 0.23 [0.18–0.31]) of malaria within a month of starting chemoprevention or developing an episode of malaria, compared to no chemoprevention or SP, this benefit decreased with time and the hazard of malaria for children who received TS was similar to those who received no chemoprevention or SP after 3.5 months of drug. Compared to no chemoprevention or SP, children who received DP had a lower risk of malaria throughout chemoprevention, but the benefit decreased over time, with a 35% lower hazard of malaria after 18 months of chemoprevention (HR [95% CI] 0.65 [0.41–0.97]; Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S7</xref>). Independent of the chemoprevention arm, HIV‐exposed children had a 21% lower hazard of malaria compared with HIV‐unexposed children (HR 0.79, 95% CI 0.66–0.91; Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S1</xref>). Each standard deviation decrease in the ZHA was associated with an 8.0% (HR 1.08, 95% CI 1.04–1.12) increase in malaria hazard.</p>
              </sec>
              <sec id="psp412892-sec-0015">
                <title>Subanalysis using <styled-content style="fixed-case" toggle="no">PQ</styled-content> concentration data</title>
                <p>Among individuals with PQ concentration data, a PQ concentration greater than 10.3 ng/ml was associated with a 36% (HR 0.64, 95% CI 0.23–0.99) decreased hazard of subsequent malaria (ΔOFV −5.6) compared to children whose most recent PQ concentration was less than or equal to 10.3 ng/ml. After accounting for PQ concentrations greater than 10.3 ng/ml, a ZHA less than −2 was associated with a twofold increased malaria hazard (HR: 2.1, 95% CI 1.6–3.0) compared to a ZHA of zero (Table <xref rid="psp412892-tbl-0004" ref-type="table">4</xref>). All other covariates tested including PQ concentration as a continuous variable were not statistically significantly associated with malaria hazard in the subanalysis (further details in the <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">Supplemental Results</xref>).</p>
              </sec>
              <sec id="psp412892-sec-0016">
                <title>Malaria, growth, and nutritional status</title>
                <p>All height, weight, and age measurements obtained after the start of chemoprevention were included in height and weight growth models. All significant covariate relationships were identified on the growth rate (KTR) of the Brody function. Cumulative prior malaria episodes (defined as the number of incident malaria episodes which occurred prior to a height measurement), ZHA and WHZ at the start of chemoprevention, and HIV exposure were associated with height (equation listed in the <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">Supplemental Methods</xref>; Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S5</xref>). Each additional episode of incident malaria was associated with a 0.4% (95% CI: 0.3% to 0.5%) decrease in growth rate for height (ΔOFV −97). Children with lower ZHA and WHZ at the start of chemoprevention had slower growth throughout the study period (Table <xref rid="psp412892-tbl-0003" ref-type="table">3</xref>). Duration of breastfeeding was highly correlated with HIV exposure. As a result, only HIV exposure status was included in the final model. HIV‐exposed children had a 58% lower growth rate compared with HIV‐unexposed children. Chemoprevention arm and socioeconomic status were not associated with the growth rate after accounting for cumulative malaria episodes. Malaria was not significantly associated with growth for weight.</p>
                <table-wrap position="float" id="psp412892-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Parameter estimates of the growth model of height</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Value (95% CI)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Between subject variability (95% CI)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Baseline height (cm)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">64.1 (63.2, 64.5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">4.7% (3.61, 4.90)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Length asymptote (cm)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">105 (102, 107)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic toggle="yes">α</italic>
                        </td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.003 (0.003, 0.004)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">23.1% (18.5, 25.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <italic toggle="yes">β</italic>
                        </td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">1.67 (1.58, 1.75)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportional error</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.016 (0.015, 0.045)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" valign="top" rowspan="1">Covariate effects</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cumulative number of malaria episodes on <italic toggle="yes">α</italic>
</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.004 (−0.006, −0.0001)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV‐exposed<xref rid="psp412892-note-0011" ref-type="table-fn"><sup>a</sup></xref> on <italic toggle="yes">α</italic>
</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.580 (−0.680, −0.248)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HIV‐exposed<xref rid="psp412892-note-0011" ref-type="table-fn"><sup>a</sup></xref> on <italic toggle="yes">β</italic>
</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.131 (0.039, 0.176)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline height‐for‐age z‐score on <italic toggle="yes">α</italic>
</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.057 (0.044, 0.086)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline weight‐for‐height z‐score on <italic toggle="yes">α</italic>
</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">0.055 (0.033, 0.078)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female on baseline height</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">−0.022 (−0.030, −0.016)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="psp412892-ntgp-0004">
                    <fn id="psp412892-note-0010">
                      <p>Abbreviations: CI, confidence interval; RSE, relative standard error.</p>
                    </fn>
                    <fn id="psp412892-note-0011">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>HIV‐exposed, indicates children who are HIV‐uninfected but were born to HIV‐infected mothers; growth rate was estimated as = <italic toggle="yes">α</italic> × Age<sup><italic toggle="yes">β</italic></sup>. The covariate relationship is given below: <mml:math id="jats-math-7" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mtext>Growth rate</mml:mtext><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mtext>Cumulative</mml:mtext><mml:mo>_</mml:mo><mml:mtext>malaria</mml:mtext></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mtext>HIVexposed</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="4pc"/><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>Baseline</mml:mtext><mml:mspace width="0.25em"/><mml:mi>ZHA</mml:mi><mml:mo>−</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mo>−</mml:mo><mml:mn>1.15</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>Baseline</mml:mtext><mml:mspace width="0.25em"/><mml:mi>WHZ</mml:mi><mml:mo>−</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mfenced><mml:mo>×</mml:mo><mml:msup><mml:mi>Age</mml:mi><mml:mrow><mml:mi>β</mml:mi><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mtext>Female</mml:mtext></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>θ</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mtext>HIVexposed</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mi>η</mml:mi></mml:msup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math>
</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="psp412892-sec-0017">
                <title>Simulations</title>
                <p>Simulations of the final survival models revealed that by 24 months of age, stunted children without chemoprevention were predicted to experience one additional malaria episode compared with children with a ZHA of zero (Table <xref rid="psp412892-tbl-0004" ref-type="table">4</xref>). DP was predicted to avert the greatest number of malaria episodes compared with no chemoprevention or SP, but the magnitude of these differences was dependent on PQ levels and nutritional status (Table <xref rid="psp412892-tbl-0004" ref-type="table">4</xref>). A preceding PQ concentration greater than 10.3 ng/ml was the most protective, with a 66% reduction in the median number of malaria episodes by 24 months of age for both stunted and non‐stunted children as compared with PQ concentrations less than or equal to 10.3 ng/ml.</p>
                <table-wrap position="float" id="psp412892-tbl-0004" content-type="TABLE">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Number of malaria episodes for stunted and non‐stunted children by piperaquine concentration</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Age (months)</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1"/>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">DP</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">No chemoprevention</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">TS</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">≤10.3 ng/ml</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&gt;10.3 ng/ml</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Non‐stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Non‐stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Non‐stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Stunted</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Non‐stunted</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">6–12</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">3 (0–6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (0–5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (0–5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (0–5)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">2 (0–6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (0–3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (0–4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0 (0–2)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">6–18</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">5 (1–10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (1–9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (1–10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (0–9)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">4 (1–10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (0–6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (0–7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (0–4)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">6–24</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">7 (2–14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (2–12)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (1–14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (1–14)</td>
                        <td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (1–15)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (0–8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (0–11)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (0–6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="psp412892-ntgp-0005">
                    <fn id="psp412892-note-0012">
                      <p><italic toggle="yes">Note</italic>: Numbers are presented as mean (5th – 95th percentiles of the simulated data); stunted: height‐for‐age z‐score = −2.1 non‐stunted: height‐for‐age Z‐score of 0; Children were assumed to be HIV‐unexposed, in the low socioeconomic category.</p>
                    </fn>
                    <fn id="psp412892-note-0013">
                      <p>Abbreviations: DP, dihydroartemisinin‐piperaquine; TS, trimethoprim‐sulfamethoxazole.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>When quantifying the impact of malaria on height and ZHA from 6 months to 3 years of age, we simulated populations with no malaria episodes, five episodes, 11 episodes, and 17 episodes. Compared with children with no malaria episodes there was a 1.3%, 3.2%, or 5.2% increase in the number of stunted children if children developed 5, 11, or 17 malaria episodes, respectively (Figure <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S4</xref>, Table <xref rid="psp412892-supitem-0001" ref-type="supplementary-material">S3</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="psp412892-sec-0018">
              <title>DISCUSSION</title>
              <p>Using parametric survival and growth modeling, we quantified the interplay between malaria and malnutrition in Ugandan children in a high perennial malaria transmission setting. Our findings indicate that improved malaria control in high transmission settings could improve overall health by reducing malnutrition, but that even when a child receives active malaria chemoprevention the risk of malaria is increased in malnourished children compared with nourished children. This indicates that further optimization of malaria chemoprevention is needed for malnourished children. In addition, we show that clinical trials and associated pharmacokinetic/pharmacodynamic (PK/PD) studies of drug‐based malaria prevention interventions should prioritize enrolling malnourished children and they should also incorporate outcomes, such as measures of malnutrition to best evaluate the intervention's health impacts.</p>
              <p>Malnutrition is highly prevalent in Africa, including in this cohort of Ugandan children. The estimated national prevalence of stunting in Ugandan children less than 5 years of age is 28.5%,<sup>2</sup> similar to the 25% of children who were stunted at the start of chemoprevention in these studies. Chronic malnutrition, as measured by low ZHA, has been reported as a risk factor for malaria.<xref rid="psp412892-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="psp412892-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="psp412892-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="psp412892-bib-0031" ref-type="bibr"><sup>31</sup></xref> However, the use of parametric survival analysis in this large cohort with rich longitudinal data and high malaria incidence allowed us to quantify how decreasing ZHA incrementally increased the risk of malaria. This continuous relationship indicates that even an incremental improvement in nutritional status could reduce a child's malaria risk.</p>
              <p>Multiple potential mechanisms for an association between malnutrition and malaria have been proposed, including malnutrition leading to reduced immunity to malaria by lowering anti‐<italic toggle="yes">P. falciparum</italic> IgG antibody response, or lower anti‐malarial drug exposure due to insufficient weight‐based dosing or lower oral bioavailability.<xref rid="psp412892-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="psp412892-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="psp412892-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="psp412892-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="psp412892-bib-0032" ref-type="bibr"><sup>32</sup></xref> Several studies in young children have identified 11–39% lower bioavailability to antimalarials associated with malnutrition.<xref rid="psp412892-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="psp412892-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="psp412892-bib-0034" ref-type="bibr"><sup>34</sup></xref> It is also possible that if malnourished children have lower <italic toggle="yes">P. falciparum</italic> immunity, they will need even higher drug exposure for full malaria protection.<xref rid="psp412892-bib-0032" ref-type="bibr"><sup>32</sup></xref> In Uganda, individuals considered to have lower immunity to <italic toggle="yes">P. falciparum</italic>, including children and primigravida pregnant women, demonstrated lower treatment responses for acute malaria or required higher drug concentrations for full malaria prevention.<xref rid="psp412892-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="psp412892-bib-0035" ref-type="bibr"><sup>35</sup></xref> Although dosing times for DP were not available for precise PK exposure estimates, after incorporating available PQ data, malnutrition remained a risk factor for malaria indicating our current methods to quantify relationships between malnutrition and PK do not fully account for the higher malaria risk for malnourished children. Modification of dose or frequency of DP have been proposed to increase chemoprevention efficacy,<xref rid="psp412892-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="psp412892-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="psp412892-bib-0037" ref-type="bibr"><sup>37</sup></xref> and optimization of chemoprevention regimens to account for nutritional status may be needed to counteract the increased risk of malaria in these children.</p>
              <p>Complementary to this finding, the Weibull distribution (increasing hazard of malaria over time) best predicted malaria hazard in the TS and DP arms, whereas in the no chemoprevention and SP arms, the hazard was constant. These differences in malaria risk trajectory by the chemoprevention arm may have been due to lower adherence to the study drugs as the study progressed or insufficient weight‐based doses as the child aged resulting in suboptimal drug exposure. PQ concentrations decreased over time as efficacy decreased in the DP arm. Dose optimization to compensate for developmental changes in drug metabolism as well as adherence interventions could be needed to improve malaria chemoprevention.</p>
              <p>Other studies have suggested malnutrition could be a confounder for socioeconomic factors that could increase malaria risk (e.g., housing construction, parental access to LLINs, or education).<xref rid="psp412892-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="psp412892-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="psp412892-bib-0039" ref-type="bibr"><sup>39</sup></xref> In our analysis, ZHA remained a significant predictor of malaria hazard after controlling for chemoprevention regimen and socioeconomic status, indicating that malnutrition is likely affecting malaria risk through a different mechanism.</p>
              <p>Although HIV‐exposed and ‐unexposed children received their care at the same study clinic and were enrolled over a similar period of time, HIV‐exposed children had a 21% lower risk of malaria compared to HIV‐unexposed children throughout the study period. A biological cause for decreased risk of malaria associated with HIV exposure is unlikely. Prior studies have found no difference in the burden of malaria between HIV‐exposed and HIV‐unexposed infants.<xref rid="psp412892-bib-0040" ref-type="bibr"><sup>40</sup></xref> However, HIV‐exposed children may have been more adherent to study drugs, had shorter follow‐up durations including fewer days in the relatively higher transmission season as compared to HIV‐unexposed children (175 vs. 253 days),<xref rid="psp412892-bib-0041" ref-type="bibr"><sup>41</sup></xref> may have been more likely to live in urban areas with lower malaria burden or reside in homes with lower parasite burdens as family members with HIV may also have taken TS compared with HIV‐unexposed participants. We controlled for differences in malaria hazard by HIV exposure, but do not expect stratifying malaria chemoprevention interventions by HIV exposure status will be needed.</p>
              <p>We found each additional malaria episode was associated with a decreased subsequent growth rate for height by 0.4%. As malaria episodes increased, so did the risk of stunting by 3 years of age. Consistent with this finding, effective malaria prevention with LLIN has been associated with significant weight and length gains in children.<xref rid="psp412892-bib-0015" ref-type="bibr"><sup>15</sup></xref> The mechanism of the relationship between malaria and growth rate is unclear, and further investigation is needed to understand the causal pathway. It is possible that without addressing concurrent illnesses, such as malaria,<xref rid="psp412892-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="psp412892-bib-0043" ref-type="bibr"><sup>43</sup></xref> nutritional interventions targeting malnutrition may not have maximum impact. Full use of longitudinal growth data to predict the impact of malaria prevention on healthy growth and development will be a key tool for quantifying the benefits of malaria control in endemic regions.</p>
              <p>This study has some limitations. First, we could not independently assess the role of breastfeeding on growth, due to confounding with HIV‐exposure. As measured, breast‐feeding did not improve growth predictions in our models, although this has been an important predictor in prior studies which assessed growth in sub‐Saharan African infants.<xref rid="psp412892-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="psp412892-bib-0045" ref-type="bibr"><sup>45</sup></xref> Second, accurate information on dosing times and adherence to study drugs was not available. As a result, we could not accurately quantify the PKs of PQ in the study population or develop a population PK/PD model, which would allow us to safely recommend optimized DP regimens for malaria chemoprevention in children less than 2 years of age. Further research in this area is needed. We note the parametric survival model slightly overpredicted the hazard of incident malaria during the initial study drug period for DP while accurately predicting the overall malaria hazard. We hypothesize this finding was due to increased adherence to DP at the beginning of the study, but further studies will be needed to evaluate these PK/PD relationships. Finally, given limitations in the available data, we could not identify the pathophysiologic mediators of the relationships between malaria and malnutrition, and this is an area which warrants future research.</p>
              <p>In conclusion, this analysis supports a bidirectional relationship between malnutrition, as measured by ZHA, and an increased risk of recurrent malaria. We found that the relationship between increased risk of malaria with lower ZHA persisted despite the choice of chemoprevention regimen, even when the most efficacious malaria chemoprevention regimen (DP) was used. Our findings suggest that optimizing chemoprevention regimens for high‐risk groups like malnourished young children, will be essential to maximize efficacy of any chemoprevention option. Further research is needed to identify the optimal chemoprevention regimens for young children with malnutrition and to evaluate how treating chronic malnutrition during infancy could improve the burden of malaria and overall health outcomes in young children.</p>
            </sec>
            <sec id="psp412892-sec-0019">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>A.M.A., E.W., E.H., G.D., and R.M.S. wrote the manuscript. A.M.A., E.W., E.H., G.D., and R.M.S. designed the research. A.M.A., E.W., and E.H. performed the research. A.M.A., E.W., R.M.S., and E.H. analyzed the data.</p>
            </sec>
            <sec id="psp412892-sec-0021">
              <title>FUNDING INFORMATION</title>
              <p>This study was supported by the Bill and Melinda Gates Foundation OPP1191117, and the National Institutes of Health KL2 TR001870‐04.</p>
            </sec>
            <sec sec-type="COI-statement" id="psp412892-sec-0022">
              <title>CONFLICT OF INTEREST</title>
              <p>The authors declared no competing interests for this work.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="psp412892-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S1
</p>
                </caption>
                <media xlink:href="PSP4-12-656-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="psp412892-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S2
</p>
                </caption>
                <media xlink:href="PSP4-12-656-s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="psp412892-supitem-0003" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S3
</p>
                </caption>
                <media xlink:href="PSP4-12-656-s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="psp412892-supitem-0004" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S4
</p>
                </caption>
                <media xlink:href="PSP4-12-656-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="psp412892-sec-0020">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors would like to thank all of the study participants and their families and the researchers and study team who conducted the clinical trials described in this analysis. We thank Dr. Marjorie Imperial, Craig Shaffer, and the UCSF Drug Research Unit researchers and staff. We extend our thanks to the Bill and Melinda Gates Foundation (Investment ID OPP1191117) for their kind support of Dr. Ali Mohamed and for the support of training pharmacometricians in Africa.</p>
            </ack>
            <ref-list content-type="cited-references" id="psp412892-bibl-0001">
              <title>REFERENCES</title>
              <ref id="psp412892-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="book" id="psp412892-cit-0001"><collab collab-type="authors">World Health Organization</collab>
. <source>World Malaria Report 2021</source>. <publisher-name>WHO</publisher-name>; <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="miscellaneous" id="psp412892-cit-0002"><article-title>Global Nutrition Report <italic toggle="yes">2020 Global Nutrition Report: Action on Equity to End Malnutrition</italic>, Bristol, UK</article-title>, <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0003"><string-name><surname>Black</surname><given-names>RE</given-names></string-name>, <string-name><surname>Victora</surname><given-names>CG</given-names></string-name>, <string-name><surname>Walker</surname><given-names>SP</given-names></string-name>, et al. <article-title>Maternal and child undernutrition and overweight in low‐income and middle‐income countries</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>382</volume>:<fpage>427</fpage>‐<lpage>451</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(13)60937-X</pub-id>
<pub-id pub-id-type="pmid">23746772</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0004"><string-name><surname>Amoah</surname><given-names>B</given-names></string-name>, <string-name><surname>Giorgi</surname><given-names>E</given-names></string-name>, <string-name><surname>Heyes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>van Burren</surname><given-names>S</given-names></string-name>, <string-name><surname>Diggle</surname><given-names>PJ</given-names></string-name>. <article-title>Geostatistical modelling of the association between malaria and child growth in Africa</article-title>. <source>Int J Health Geogr</source>. <year>2018</year>;<volume>17</volume>:<fpage>7</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12942-018-0127-y</pub-id><pub-id pub-id-type="pmid">29482559</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0005"><string-name><surname>Arinaitwe</surname><given-names>E</given-names></string-name>, <string-name><surname>Gasasira</surname><given-names>A</given-names></string-name>, <string-name><surname>Verret</surname><given-names>W</given-names></string-name>, et al. <article-title>The association between malnutrition and the incidence of malaria among young HIV‐infected and ‐uninfected Ugandan children: a prospective study</article-title>. <source>Malar J</source>. <year>2012</year>;<volume>11</volume>:<fpage>1</fpage>‐<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-11-90</pub-id>
<pub-id pub-id-type="pmid">22212246</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0006"><string-name><surname>Nyakeriga</surname><given-names>AM</given-names></string-name>, <string-name><surname>Troye‐Blomberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Chemtai</surname><given-names>AK</given-names></string-name>, <string-name><surname>Marsh</surname><given-names>K</given-names></string-name>, <string-name><surname>Williams</surname><given-names>TN</given-names></string-name>. <article-title>Malaria and nutritional status in children living on the coast of Kenya</article-title>. <source>Am J Clin Nutr</source>. <year>2004</year>;<volume>80</volume>:<fpage>1604</fpage>‐<lpage>1614</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajcn/80.6.1604</pub-id>
<pub-id pub-id-type="pmid">15585775</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0007"><string-name><surname>Friedman</surname><given-names>JF</given-names></string-name>, <string-name><surname>Kwena</surname><given-names>AM</given-names></string-name>, <string-name><surname>Mirel</surname><given-names>LB</given-names></string-name>, et al. <article-title>Malaria and nutritional status among pre‐school children: results from cross‐sectional surveys in western Kenya</article-title>. <source>Am J Trop Med Hyg</source>. <year>2005</year>;<volume>73</volume>:<fpage>698</fpage>‐<lpage>704</lpage>.<pub-id pub-id-type="pmid">16222012</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0008"><string-name><surname>Das</surname><given-names>D</given-names></string-name>, <string-name><surname>Grais</surname><given-names>RF</given-names></string-name>, <string-name><surname>Okiro</surname><given-names>EA</given-names></string-name>, et al. <article-title>Complex interactions between malaria and malnutrition: a systematic literature review</article-title>. <source>BMC Med</source>. <year>2018</year>;<volume>16</volume>:<fpage>186</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12916-018-1177-5</pub-id><pub-id pub-id-type="pmid">30371344</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0009"><string-name><surname>Fillol</surname><given-names>F</given-names></string-name>, <string-name><surname>Sarr</surname><given-names>JB</given-names></string-name>, <string-name><surname>Boulanger</surname><given-names>D</given-names></string-name>, et al. <article-title>Impact of child malnutrition on the specific anti‐plasmodium falciparum antibody response</article-title>. <source>Malar J</source>. <year>2009</year>;<volume>8</volume>:<fpage>1</fpage>‐<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-8-116</pub-id>
<pub-id pub-id-type="pmid">19118502</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0010"><string-name><surname>Hoglund</surname><given-names>RM</given-names></string-name>, <string-name><surname>Workman</surname><given-names>L</given-names></string-name>, <string-name><surname>Edstein</surname><given-names>MD</given-names></string-name>, et al. <article-title>Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta‐analysis</article-title>. <source>PLoS Med</source>. <year>2017</year>;<volume>14</volume>:<fpage>e1002212</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1002212</pub-id><pub-id pub-id-type="pmid">28072872</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0011"><string-name><surname>Sambol</surname><given-names>NC</given-names></string-name>, <string-name><surname>Yan</surname><given-names>L</given-names></string-name>, <string-name><surname>Creek</surname><given-names>DJ</given-names></string-name>, et al. <article-title>Population pharmacokinetics of piperaquine in Young Ugandan children treated with dihydroartemisinin‐piperaquine for uncomplicated malaria</article-title>. <source>Clin Pharmacol Ther</source>. <year>2015</year>;<volume>98</volume>:<fpage>87</fpage>‐<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.104</pub-id>
<pub-id pub-id-type="pmid">25732044</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0012"><string-name><surname>Siri</surname><given-names>JG</given-names></string-name>. <article-title>Independent associations of maternal education and household wealth with malaria risk in children</article-title>. <source>Ecol Soc</source>. <year>2014</year>;<volume>19</volume>. doi:<pub-id pub-id-type="doi">10.5751/ES-06134-190133</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0013"><string-name><surname>Krefis</surname><given-names>AC</given-names></string-name>, <string-name><surname>Schwarz</surname><given-names>NG</given-names></string-name>, <string-name><surname>Nkrumah</surname><given-names>B</given-names></string-name>, et al. <article-title>Principal component analysis of socioeconomic factors and their association with malaria in children from the Ashanti region, Ghana</article-title>. <source>Malar J</source>. <year>2010</year>;<volume>9</volume>:<fpage>1</fpage>‐<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-9-201</pub-id>
<pub-id pub-id-type="pmid">20043863</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0014"><string-name><surname>Njau</surname><given-names>JD</given-names></string-name>, <string-name><surname>Stephenson</surname><given-names>R</given-names></string-name>, <string-name><surname>Menon</surname><given-names>MP</given-names></string-name>, <string-name><surname>Kachur</surname><given-names>SP</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>DA</given-names></string-name>. <article-title>Investigating the important correlates of maternal education and childhood malaria infections</article-title>. <source>Am J Trop Med Hyg</source>. <year>2014</year>;<volume>91</volume>:<fpage>509</fpage>‐<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.4269/ajtmh.13-0713</pub-id>
<pub-id pub-id-type="pmid">25002302</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0015"><string-name><surname>ter Kuile</surname><given-names>FO</given-names></string-name>, <string-name><surname>Terlouw</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Kariuki</surname><given-names>SK</given-names></string-name>, et al. <article-title>Impact of permethrin‐treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya</article-title>. <source>Am J Trop Med Hyg</source>. <year>2003</year>;<volume>64</volume>:<fpage>68</fpage>‐<lpage>77</lpage>.</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0016"><string-name><surname>Deribew</surname><given-names>A</given-names></string-name>, <string-name><surname>Alemseged</surname><given-names>F</given-names></string-name>, <string-name><surname>Tessema</surname><given-names>F</given-names></string-name>, et al. <article-title>Malaria and under‐nutrition: a community based study among under‐five children at risk of malaria, South‐West Ethiopia</article-title>. <source>PLoS ONE</source>. <year>2010</year>;<volume>5</volume>:<fpage>1</fpage>‐<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0010775</pub-id>
</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0017"><string-name><surname>Müller</surname><given-names>O</given-names></string-name>, <string-name><surname>Garenne</surname><given-names>M</given-names></string-name>, <string-name><surname>Kouyaté</surname><given-names>B</given-names></string-name>, <string-name><surname>Becher</surname><given-names>H</given-names></string-name>. <article-title>The association between protein‐energy malnutrition, malaria morbidity and all‐cause mortality in West African children</article-title>. <source>Trop Med Int Health</source>. <year>2003</year>;<volume>8</volume>:<fpage>507</fpage>‐<lpage>511</lpage>.<pub-id pub-id-type="pmid">12791055</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0018"><string-name><surname>Bigira</surname><given-names>V</given-names></string-name>, <string-name><surname>Kapisi</surname><given-names>J</given-names></string-name>, <string-name><surname>Clark</surname><given-names>TD</given-names></string-name>, et al. <article-title>Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial</article-title>. <source>PLoS Med</source>. <year>2015</year>;<volume>11</volume>:<fpage>e1001689</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1001689</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0019"><string-name><surname>Kamya</surname><given-names>MR</given-names></string-name>, <string-name><surname>Kapisi</surname><given-names>J</given-names></string-name>, <string-name><surname>Bigira</surname><given-names>V</given-names></string-name>, et al. <article-title>Efficacy and safety of three regimens for the prevention of malaria in young HIV‐exposed Ugandan children: a randomized controlled trial</article-title>. <source>AIDS</source>. <year>2014</year>;<volume>28</volume>:<fpage>2701</fpage>‐<lpage>2709</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0000000000000497</pub-id>
<pub-id pub-id-type="pmid">25493596</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="book" id="psp412892-cit-0020"><collab collab-type="authors">World Health Organization</collab>
. <source>WHO Child Growth Standards – Methods and Development</source>. <publisher-name>WHO</publisher-name>; <year>2007</year>.</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="book" id="psp412892-cit-0021"><collab collab-type="authors">World Health Organization</collab>
. <source>WHO Child Growth Standards STATA Igrowup Package</source>. <publisher-name>WHO</publisher-name>; <year>2006</year>.</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0022"><string-name><surname>Sundell</surname><given-names>K</given-names></string-name>, <string-name><surname>Jagannathan</surname><given-names>P</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name>, et al. <article-title>Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin‐piperaquine for the prevention of malaria in Ugandan children</article-title>. <source>Malar J</source>. <year>2015</year>;<volume>14</volume>:<fpage>368</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12936-015-0908-8</pub-id><pub-id pub-id-type="pmid">26403465</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0023"><string-name><surname>Kjellin</surname><given-names>LL</given-names></string-name>, <string-name><surname>Dorsey</surname><given-names>G</given-names></string-name>, <string-name><surname>Rosenthal</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Aweeka</surname><given-names>F</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name>. <article-title>Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC‐MS/MS</article-title>. <source>Bioanalysis</source>. <year>2014</year>;<volume>6</volume>:<fpage>3081</fpage>‐<lpage>3089</lpage>. doi:<pub-id pub-id-type="doi">10.4155/bio.14.254</pub-id>
<pub-id pub-id-type="pmid">25529877</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="book" id="psp412892-cit-0024"><string-name><surname>Bonate</surname><given-names>PL</given-names></string-name>. <source>Pharmacokinetic‐Pharmacodynamic Modeling and Simulation</source>. <publisher-name>Springer US</publisher-name>; <year>2011</year>. doi:<pub-id pub-id-type="doi">10.1007/978-1-4419-9485-1</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0025"><string-name><surname>Nguyen</surname><given-names>THT</given-names></string-name>, <string-name><surname>Mouksassi</surname><given-names>MS</given-names></string-name>, <string-name><surname>Holford</surname><given-names>N</given-names></string-name>, et al. <article-title>Model evaluation of continuous data pharmacometric models: metrics and graphics</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2017</year>;<volume>6</volume>:<fpage>87</fpage>‐<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.12161</pub-id>
<pub-id pub-id-type="pmid">27884052</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0026"><string-name><surname>Huh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hutmacher</surname><given-names>MM</given-names></string-name>. <article-title>Application of a hazard‐based visual predictive check to evaluate parametric hazard models</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2016</year>;<volume>43</volume>:<fpage>57</fpage>‐<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10928-015-9454-9</pub-id>
<pub-id pub-id-type="pmid">26563504</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0027"><string-name><surname>Savic</surname><given-names>RM</given-names></string-name>, <string-name><surname>Jagannathan</surname><given-names>P</given-names></string-name>, <string-name><surname>Kajubi</surname><given-names>R</given-names></string-name>, et al. <article-title>Intermittent preventive treatment for malaria in pregnancy: optimization of target concentrations of Dihydroartemisinin‐piperaquine</article-title>. <source>Clin Infect Dis</source>. <year>2018</year>;<volume>67</volume>:<fpage>1079</fpage>‐<lpage>1088</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciy218</pub-id>
<pub-id pub-id-type="pmid">29547881</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0028"><string-name><surname>Chotsiri</surname><given-names>P</given-names></string-name>, <string-name><surname>Zongo</surname><given-names>I</given-names></string-name>, <string-name><surname>Milligan</surname><given-names>P</given-names></string-name>, et al. <article-title>Optimal dosing of dihydroartemisinin‐piperaquine for seasonal malaria chemoprevention in young children</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>:<fpage>480</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-08297-9</pub-id><pub-id pub-id-type="pmid">30696903</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0029"><string-name><surname>Wallender</surname><given-names>E</given-names></string-name>, <string-name><surname>Ali</surname><given-names>AM</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>E</given-names></string-name>, et al. <article-title>Identifying an optimal dihydroartemisinin‐piperaquine dosing regimen for malaria prevention in young Ugandan children</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>:<fpage>6714</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-27051-8</pub-id><pub-id pub-id-type="pmid">34795281</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0030"><string-name><surname>Shikur</surname><given-names>B</given-names></string-name>, <string-name><surname>Deressa</surname><given-names>W</given-names></string-name>, <string-name><surname>Lindtjørn</surname><given-names>B</given-names></string-name>. <article-title>Association between malaria and malnutrition among children aged under‐five years in Adami Tulu District, south‐Central Ethiopia: a case‐control study</article-title>. <source>BMC Public Health</source>. <year>2016</year>;<volume>16</volume>:<fpage>174</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12889-016-2838-y</pub-id><pub-id pub-id-type="pmid">26895759</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0031"><string-name><surname>Sakwe</surname><given-names>N</given-names></string-name>, <string-name><surname>Bigoga</surname><given-names>J</given-names></string-name>, <string-name><surname>Ngondi</surname><given-names>J</given-names></string-name>, et al. <article-title>Relationship between malaria, anaemia, nutritional and socio‐economic status amongst under‐ten children, in the north region of Cameroon: a cross‐sectional assessment</article-title>. <source>PLoS ONE</source>. <year>2019</year>;<volume>14</volume>:<fpage>e0218442</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0218442</pub-id><pub-id pub-id-type="pmid">31226133</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0032"><string-name><surname>Greenhouse</surname><given-names>B</given-names></string-name>, <string-name><surname>Slater</surname><given-names>M</given-names></string-name>, <string-name><surname>Njama‐Meya</surname><given-names>D</given-names></string-name>, et al. <article-title>Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance</article-title>. <source>J Infect Dis</source>. <year>2009</year>;<volume>199</volume>:<fpage>758</fpage>‐<lpage>765</lpage>. doi:<pub-id pub-id-type="doi">10.1086/596741</pub-id>
<pub-id pub-id-type="pmid">19199542</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0033"><string-name><surname>Chotsiri</surname><given-names>P</given-names></string-name>, <string-name><surname>Denoeud‐Ndam</surname><given-names>L</given-names></string-name>, <string-name><surname>Baudin</surname><given-names>E</given-names></string-name>, et al. <article-title>Severe acute malnutrition results in lower lumefantrine exposure in children treated with artemether‐lumefantrine for uncomplicated malaria</article-title>. <source>Clin Pharmacol Ther</source>. <year>2019</year>;<volume>106</volume>:<fpage>1299</fpage>‐<lpage>1309</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.1531</pub-id>
<pub-id pub-id-type="pmid">31152555</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0034"><string-name><surname>de Kock</surname><given-names>M</given-names></string-name>, <string-name><surname>Tarning</surname><given-names>J</given-names></string-name>, <string-name><surname>Workman</surname><given-names>L</given-names></string-name>, et al. <article-title>Population pharmacokinetic properties of Sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2018</year>;<volume>62</volume>:<fpage>e01370</fpage>‐<lpage>e01317</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01370-17</pub-id>
<pub-id pub-id-type="pmid">29463542</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0035"><string-name><surname>Wallender</surname><given-names>E</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name><surname>Conrad</surname><given-names>M</given-names></string-name>, et al. <article-title>Modeling prevention of malaria and selection of drug resistance with different dosing schedules of Dihydroartemisinin‐piperaquine preventive therapy during pregnancy in Uganda</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2019</year>;<volume>63</volume>:<fpage>e1393</fpage>‐<lpage>e1318</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01393-18</pub-id>
</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0036"><string-name><surname>Sambol</surname><given-names>NC</given-names></string-name>, <string-name><surname>Tappero</surname><given-names>JW</given-names></string-name>, <string-name><surname>Arinaitwe</surname><given-names>E</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>S</given-names></string-name>. <article-title>Rethinking dosing regimen selection of piperaquine for malaria chemoprevention: a simulation study</article-title>. <source>PLoS ONE</source>. <year>2016</year>;<volume>11</volume>:<fpage>e0154623</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0154623</pub-id><pub-id pub-id-type="pmid">27182702</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0037"><string-name><surname>Hughes</surname><given-names>E</given-names></string-name>, <string-name><surname>Imperial</surname><given-names>M</given-names></string-name>, <string-name><surname>Wallender</surname><given-names>E</given-names></string-name>, et al. <article-title>Piperaquine exposure is altered by pregnancy, HIV, and nutritional status in Ugandan women</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>:<fpage>1</fpage>‐<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01013-20</pub-id>
</mixed-citation>
              </ref>
              <ref id="psp412892-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0038"><string-name><surname>Snyman</surname><given-names>K</given-names></string-name>, <string-name><surname>Mwangwa</surname><given-names>F</given-names></string-name>, <string-name><surname>Bigira</surname><given-names>V</given-names></string-name>, et al. <article-title>Poor housing construction associated with increased malaria incidence in a cohort of young Ugandan children</article-title>. <source>Am J Trop Med Hyg</source>. <year>2015</year>;<volume>92</volume>:<fpage>1207</fpage>‐<lpage>1213</lpage>. doi:<pub-id pub-id-type="doi">10.4269/ajtmh.14-0828</pub-id>
<pub-id pub-id-type="pmid">25870429</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0039"><string-name><surname>Slutsker</surname><given-names>L</given-names></string-name>, <string-name><surname>Khoromana</surname><given-names>CO</given-names></string-name>, <string-name><surname>Hightower</surname><given-names>AW</given-names></string-name>, et al. <article-title>Malaria infection in infancy in rural Malawi</article-title>. <source>Am J Trop Med Hyg</source>. <year>1996</year>;<volume>55</volume>:<fpage>71</fpage>‐<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.4269/ajtmh.1996.55.71</pub-id>
<pub-id pub-id-type="pmid">8702041</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0040"><string-name><surname>Osterbauer</surname><given-names>B</given-names></string-name>, <string-name><surname>Kapisi</surname><given-names>J</given-names></string-name>, <string-name><surname>Bigira</surname><given-names>V</given-names></string-name>, et al. <article-title>Factors associated with malaria parasitaemia, malnutrition, and anaemia among HIV‐exposed and unexposed Ugandan infants: a cross‐sectional survey</article-title>. <source>Malar J</source>. <year>2012</year>;<volume>11</volume>:<fpage>1</fpage>‐<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-11-432</pub-id>
<pub-id pub-id-type="pmid">22212246</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0041"><string-name><surname>Kamya</surname><given-names>MR</given-names></string-name>, <string-name><surname>Arinaitwe</surname><given-names>E</given-names></string-name>, <string-name><surname>Wanzira</surname><given-names>H</given-names></string-name>, et al. <article-title>Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control</article-title>. <source>Am J Trop Med Hyg</source>. <year>2015</year>;<volume>92</volume>:<fpage>903</fpage>‐<lpage>912</lpage>. doi:<pub-id pub-id-type="doi">10.4269/ajtmh.14-0312</pub-id>
<pub-id pub-id-type="pmid">25778501</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0042"><string-name><surname>Källander</surname><given-names>K</given-names></string-name>, <string-name><surname>Nsungwa‐Sabiiti</surname><given-names>J</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>S</given-names></string-name>. <article-title>Symptom overlap for malaria and pneumonia ‐ policy implications for home management strategies</article-title>. <source>Acta Trop</source>. <year>2004</year>;<volume>90</volume>:<fpage>211</fpage>‐<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actatropica.2003.11.013</pub-id>
<pub-id pub-id-type="pmid">15177148</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0043"><string-name><surname>Mulholland</surname><given-names>K</given-names></string-name>. <article-title>Commentary: comorbidity as a factor in child health and child survival in developing countries</article-title>. <source>Int J Epidemiol</source>. <year>2005</year>;<volume>34</volume>:<fpage>375</fpage>‐<lpage>377</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ije/dyi028</pub-id>
<pub-id pub-id-type="pmid">15764692</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0044"><string-name><surname>Takele</surname><given-names>K</given-names></string-name>, <string-name><surname>Zewotir</surname><given-names>T</given-names></string-name>, <string-name><surname>Ndanguza</surname><given-names>D</given-names></string-name>. <article-title>Understanding correlates of child stunting in Ethiopia using generalized linear mixed models</article-title>. <source>BMC Public Health</source>. <year>2019</year>;<volume>19</volume>:<fpage>626</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12889-019-6984-x</pub-id><pub-id pub-id-type="pmid">31118013</pub-id></mixed-citation>
              </ref>
              <ref id="psp412892-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="psp412892-cit-0045"><string-name><surname>Faye</surname><given-names>CM</given-names></string-name>, <string-name><surname>Fonn</surname><given-names>S</given-names></string-name>, <string-name><surname>Levin</surname><given-names>J</given-names></string-name>, <string-name><surname>Kimani‐Murage</surname><given-names>E</given-names></string-name>. <article-title>Analysing child linear growth trajectories among under‐5 children in two Nairobi informal settlements</article-title>. <source>Public Health Nutr</source>. <year>2019</year>;<volume>22</volume>:<fpage>2001</fpage>‐<lpage>2011</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1368980019000491</pub-id>
<pub-id pub-id-type="pmid">30940271</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
